Share
   
Title
E-posters Track B
Session Type
E-Posters

PEB0088 The feasibility and challenges of diagnosing and treating acute HIV infection in a resource limited high HIV incidence setting in Eswatini
Bernhard Kerschberger, Médecins Sans Frontières, Eswatini
Abstract
PDF
PEB0089 Rapid initiation of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in acute and early human immunodeficiency virus (HIV)–1 infection: A DIAMOND subgroup analysis
Rachel Rogers, Janssen Scientific Affairs, LLC, United States
Abstract
Slides
PEB0090 Evaluation of viral suppression one year after genotyping test to guide salvage therapy among adult patients infected with HIV-1 B or HIV-1 F subtype at polymerase region
Cintia Mayumi Ahagon, Instituto Adolfo Lutz, Brazil
Abstract
Slides
PEB0091 Trends in clinical follow-up between 2008-2018 among people living with HIV in the TREAT Asia and Australian HIV Observational Databases (TAHOD and AHOD)
Awachana Jiamsakul, The Kirby Institute, UNSW Sydney, Australia
Abstract
Slides
PEB0092 Causes and incidence of hospitalization in patients enrolled in the ICONA cohort
Silvia NOZZA, Ospedale San Raffaele, Italy
Abstract
Slides
PEB0093 A comparison of mortality in patients with aggressive AIDS-related lymphoma treated with and without rituximab
Pinky Manyau, University of Zimbabwe, Zimbabwe
Abstract
Slides
PEB0094 Evaluation of low level viremia in a multinational study and associations with clinical outcomes, immunologic outcomes and micronutrients
Hillary Dunlevy, University of Colorado, United States
Abstract
Slides
PEB0095 Time to ART Initiation from HIV diagnosis and survival to fatal and non-fatal severe events: An analysis of the HIV Atlanta Veterans Affairs Cohort Study, 2005-2019
Elizabeth Rabold, Centers for Disease Control and Prevention, United States
Abstract
PEB0096 Risk of hospitalisation according to demographic, socioeconomic, mental health and lifestyle factors and causes for admission in people living with HIV in the UK
Sophia Rein, University College London (UCL), United Kingdom
Abstract
Slides
PEB0097 Cohort study on HIV/AIDS-related mortality for key populations managed under programmatic conditions in Papua New Guinea: 2008 - 2019
Shepherd Mufudzi Machekera, World Vision International, Papua New Guinea
Abstract
Slides
PEB0098 Factors associated with high mortality and loss to follow-up among "challenging" patients in Argentina re-engaging in HIV care
Omar Sued, Fundación Huésped, Argentina
Abstract
PEB0099 Assessment of HIV testing recommendations in Greek specialty guidelines: A missed opportunity for recommending testing
Karolina Akinosoglou, University Hospital of Patras, Greece
Abstract
Slides
PEB0101 Evaluation of CD4 T-cells on the BD FACSLyric, BD FACSPresto and BD FACSCount Systems
Yang Zeng, BD Life Sciences, United States
Abstract
Slides
PEB0102 Exploring the contribution of Index testing in HIV case-finding in EGPAF-MACRO supported districts in Malawi: The case of Thyolo, Blantyre, Zomba, Mwanza and Chiradzulu
Patrick Mbulaje, Malawi AIDS Counseling and Resource Organisation, Malawi
Abstract
Slides
PEB0103 Test performance of the new version of Serodia agglutination test in HIV-1 infected Thai patients
Supanit Pattanachaiwit, Thai Red Cross AIDS Research Centre, Thailand
Abstract
Slides
PEB0104 Randomized comparison of the preference and usability of two HIV self-testing kits among Australian gay and bisexual men
Jason J. Ong, Monash University, Australia
Abstract
Slides
PEB0105 Does ART contribute to false-negative results in routine PMTCT testing? Evidence from national HIV surveillance in Zimbabwe
Louisa Moorhouse, Imperial College London, United Kingdom
Abstract
Slides
PEB0107 Evaluation of an emergency department-based opt-out HIV screening program in South Florida
paula eckardt, Memorial Healthcare System, United States
Abstract
Slides
PEB0108 Integration of screening risk behavior and symptoms suggestive of HIV infection into national HIV testing services in Mozambique, 2019
Guita Amane, MOH, Mozambique
Abstract
Slides
PEB0109 Decentralized EID and VL testing in Senegal: Results from the Point-of-Care pilot
Khady Diatou Coulibaly, Division of AIDS Control /STI, Senegal
Abstract
Slides
PEB0110 Using Point-of-Care testing operated by non-technical staff to improve healthcare provision to infants exposed to HIV in Mozambique
Chishamiso Mudenyanga, New Innovation Systems, Clinton Health Access Initiative, Mozambique
Abstract
PEB0111 Factors associated with high-level viremia in South African adults on antiretroviral therapy: A recurrent events analysis from an 8-year prospective cohort study
Fortunate Nonhlanhla Yende-Zuma, Centre for the AIDS Programme of Research in South Africa (CAPRISA), South Africa
Abstract
Slides
PEB0112 Virologic outcomes among patients on first-line antiretroviral therapy (ART) following transition to dolutegravir in a tertiary HIV clinic in Uganda
Abdullah Wailagala, Infectious Diseases Institute, Uganda
Abstract
Slides
PEB0113 Need for improved demand creation and accelerated viral load testing coverage to meet UNAIDS HIV treatment targets
George Alemnji, Office of the Global AIDS Coordinator and Health Diplomacy (OGAC), United States
Abstract
Slides
PEB0114 Improving documented Viral Load suppression results among People Living with HIV in Urban Lusaka
Katamba Patrick Cibangu, Lusaka Provincial Health Office, Zambia
Abstract
Slides
PEB0115 Effectiveness of enhanced adherence counseling at achieving viral suppression among virally unsuppressed HIV positive clients in Nasarawa State, Nigeria
EMMANUEL CHUKWU, Aids Healthcare Foundation, Nigeria
Abstract
Slides
PEB0116 Increased HIV-1 pretreatment drug resistance with consistent clade homogeneity among ART-naive HIV-1 infected individuals in Ethiopia
Mulugeta Kiros, Addis Ababa University, Ethiopia
Abstract
Slides
PEB0117 High drug resistance levels compromise the control of HIV in paediatric and adolescent population in Kinshasa, Democratic Republic of Congo
Marina Rubio-Garrido, Hospital Ramón y Cajal, Spain
Abstract
Slides
PEB0118 Significance of archived HIV resistant associated mutations in the era of two drug ART therapy
smitha gudipati, Henry Ford Health System, United States
Abstract
Slides
PEB0119 Low level viremia in naïve and experienced HIV+ patients beginning different integrase strand-transfer inhibitor-based regimen
Manuela Ceccarelli, University of Catania, Italy
Abstract
PEB0121 High rates of NNRTI and NRTI resistance in children and adolescents in Haiti: Impact on future treatment options
Nadalette Alcénat, GHESKIO Centers, Haiti
Abstract
Slides
PEB0122 Ibalizumab shows in vitro activity against group A and group B HIV-2 clinical isolates
Charlotte Charpentier, Hôpital Bichat-Claude Bernard, Laboratoire de Virologie, Université de Paris, INSERM IAME UMR1137, France
Abstract
Slides
PEB0123 Comparison of 3 immunodiagnostic tests for Latent Tuberculosis infection among Thai prisoners
Sasiwimol Ubolyam, HIV Netherlands Australia Thailand Research Collaboration, The Thai Red Cross AIDS Research Center, Thailand
Abstract
Slides
PEB0124 Diagnostic performance of multiplexed platform and point-of-care rapid tests for HIV and sexually-transmitted blood-borne infections: A systematic review
Angela Karellis, McGill University, Canada
Abstract
Slides
PEB0125 Indirect ophthalmoscopy as a screening tool for the diagnosis of opportunistic infections in hospitalized patients with advanced HIV disease in Maputo, Mozambique
Ana Gabriela Gutierrez, Médecins sans Frontiéres, Mozambique
Abstract
PEB0126 Mitochondrial DNA "common deletion" is inversely associated with neuroinflammation and neurodegeneration in people with HIV
Dipesh Solanky, University of California, San Diego, United States
Abstract
Slides
PEB0127 Urinary exosome-derived micro-RNAs as biomarkers for tenofovir disoproxil fumarate-associated (TDF) renal toxicity in HIV-1-infected patients
Jose Luis Casado, Ramon y Cajal Hospital, Spain
Abstract
Slides
PEB0128 The tuberculosis care cascade in Zambia: Identifying the gaps in order to improve outcomes
Andrew Kerkhoff, University of California San Francisco, United States
Abstract
Slides
PEB0129 Enhancing TB diagnosis in HIV+ patients in Kenya: Preliminary results of IDEA-TB study in a cohort from DREAM program
Kristien Wouters, Institute of Tropical Medicine, Belgium
Abstract
Slides
PEB0130 Radiographers' role extension in Rwanda: Ultrasonographic detection of abdominal tuberclosius in HIV/AIDS patients in rural district hospitals
Olivier Mizero, Rwanda Military Hospital, Rwanda
Abstract
Slides
PEB0131 Enhanced tuberculosis screening and diagnosis for hospitalized individuals in a high HIV prevalence setting in KwaZulu-Natal, South Africa: A before and after study
Abera Balcha Bulti, Médecins Sans Frontières (MSF), South Africa
Abstract
Slides
PEB0132 Systematic lateral flow urine lipoarabinomannan assay (LF-LAM) for diagnosis of tuberculosis among HIV positive hospitalized patients in KwaZulu-Natal, South Africa
Asnake Yohannes Dumicho, Médecins Sans Frontières (MSF), South Africa
Abstract
Slides
PEB0133 What is the performance of Tuberculosis management among People Living with HIV in HIV care and treatment settings in Tanzania?
Werner Maokola, Ministry of Health,Community Development,Gender,Elderly and Children, Tanzania, United Republic of
Abstract
Slides
PEB0134 Isoniazid anti-tuberculosis chemoprophylaxis in HIV-infected patients
fatima ihbibane, Faculty of Medicine and Pharmacy- Cadi Ayyad University- university hospital center Mohamed VI, Morocco
Abstract
PEB0135 Delays and barriers to health-seeking among newly diagnosed tuberculosis patients in Zambia
Andrew Kerkhoff, University of California San Francisco, United States
Abstract
Slides
PEB0136 Effect of tuberculosis infection on mortality among HIV-infected patients in Northern Tanzania
Edson Mollel, Kilimanjaro Christian Medical University College, Tanzania, United Republic of
Abstract
Slides
PEB0137 Tuberculosis and cryptococcal co-morbidity among patients with advanced HIV disease in Lesotho
Vincent J Tukei, Elizabeth Glaser Pediatric AIDS Foundation, Lesotho
Abstract
Slides
PEB0138 Screening and treatment strategies for latent tuberculosis infection in newly HIV diagnosed people living in low-endemic country: A simulation for Italy
Abstract
PEB0139 A comparative analysis of adherence and completion rates in TB preventive therapy (TPT) among people living with HIV on 3-months & 6-months multi-months ART dispensing
KUNLE KAKANFO, Family Health International (FHI360, Nigeria), Nigeria
Abstract
Slides
PEB0140 High prevalence of venous thromboembolic disease among HIV patients co-infected with drug-resistant TB in Lesotho
David Holtzman, Partners In Health - Lesotho, Lesotho
Abstract
Slides
PEB0141 Do people living with HIV/AIDS know and adhere to isoniazid preventive therapy?: Findings from selected facilities in South-East Nigeria
Ijeoma Okedo-Alex, Federal Teaching Hospital Abakaliki Ebonyi State, Nigeria
Abstract
Slides
PEB0142 Sensitivity and specificity of Xpert Ultra and predictive value of symptoms of tuberculosis in patients newly diagnosed with HIV
Nancy Dorvil, GHESKIO, Haiti
Abstract
PEB0144 The frequency and yield of cryptococcal antigen screening among newly diagnosed and anti-retroviral therapy experienced HIV patients in rural Uganda
Joseph Baruch Baluku, Mildmay Uganda, Uganda
Abstract
Slides
PEB0145 CMV co-infection in HIV elite controllers: Importance for disease progression and inflammation
Jean-Pierre Routy, McGill university Health Centre, Canada
Abstract
PDF
PEB0146 Pathogenic spectrum and clinical characteristics of pulmonary filamentous fungal infection in AIDS patients in Guangdong area
Linghua Li, Guangzhou Eighth People's Hospital, China
Abstract
Slides
PEB0147 Severe anaemia is associated with latent tuberculosis among people living with HIV
Matemo Daniel, Kenyatta National Hospital, Kenya
Abstract
Slides
PEB0148 Racial/ethnical disparities in HCV testing among MSM in HIV care
Jun Li, CDC, United States
Abstract
Slides
PEB0149 Prevalence and predictors of tobacco use in patients living with HIV/HCV co-infection: Findings from a large urban tertiary center
Omar Sims, University of Alabama at Birmingham, United States
Abstract
Slides
PEB0150 Evolution of HIV reservoir and viral splicing after the elimination of HCV with DAAs in HIV/HCV patients
Paula Martínez Román, Institute of Health Carlos III, Spain
Abstract
Slides
PEB0151 Costs and clinical outcomes of a simplified HCV treatment algorithm for Ukraine
Charles Chasela, Right to Care, South Africa
Abstract
PEB0152 High SVR with ledipasvir/sofosbuvir +/- ribavirin among PWID and PWH in Ukraine
Charles Chasela, Right to Care, South Africa
Abstract
PEB0153 Creating a multi-site HCV care cascade for HIV/HCV co-infected persons receiving care in 11 CT clinics using data to care methods
Ralph Brooks, Yale University, United States
Abstract
Slides
PEB0154 Predictors associated with better response to Japanese aluminum-free hepatitis A vaccine to Japanese people living with HIV: Lessons from the hepatitis A outbreaks in Tokyo
Michiko Koga, The Institute of Medical Science, The University of Tokyo, Japan
Abstract
PEB0155 High co-infection with HBV, HCV and syphilis, and low CD4/CD8 ratio among HIV/AIDS patients in Guangzhou, China 2014-2017
Abstract
PEB0156 Serologic response to hepatitis A vaccination among HIV-infected individuals
Takashi Muramatsu, Tokyo Medical University Hospital, Japan
Abstract
Slides
PEB0157 Hepatitis B co-infection in HIV-infected patients receiving multi-drug resistant tuberculosis (MDRTB) treatment at the Botsabelo Hospital in Lesotho
Lawrence Oyewusi, Partners In Health Lesotho /Bo-Mphato Litšebeletsong tsa Bophelo, Lesotho
Abstract
Slides
PEB0158 Burden of Human Papillomavirus infection among HIV positive women in North Central Nigeria: A cross sectional study
Chinenye Anaedobe, University of Abuja Teaching Hospital, Nigeria
Abstract
Slides
PEB0159 Prevalence and characteristics of anal papillomavirus infection in a Cohort of HIV-positive men who have sex with men in Lima, Peru
Jaime A. Collins, Infectious Diseases Service, Almenara Hospital, EsSalud, Peru
Abstract
Slides
Slides
PEB0160 Clinical and laboratory aspects of patients with asymptomatic neurosyphilis and HIV infection treated with ceftriaxone: A retrospective cohort
ANA LUIZA DE CASTRO CONDE TOSCANO, Emilio Ribas Infectious Diseases Institute, Brazil
Abstract
Slides
PEB0162 Dramatic increase of macrolide resistance in Treponema pallidum isolates in Argentina
Nicolas Morando, Instituto de Investigaciones Biomédicas en Retrovirus y SIDA, Argentina
Abstract
Slides
PEB0163 Incorporation of screening and treatment for sexually transmitted infections into routine care for patients living with HIV in Gaborone, Botswana
Sophie Dunin De Skrzynno, Botswana-UPenn Partnership (BUP), Botswana
Abstract
Slides
PEB0165 Discover study for HIV Pre-Exposure Prophylaxis (PrEP): No evidence of risk compensation in participants taking F/TDF or F/TAF for PrEP through 96 weeks
Peter Shalit, Peter Shalit MD, United States
Abstract
PDF
PEB0166 Anal cytological abnormalities and HPV detection with different primer sets in HIV-positive men in eastern India
Jaya Chakravarty, Institute of Medical Sciences, Banaras Hindu University, India
Abstract
Slides
PEB0167 Clinical prediction of Chlamydia trachomatis and Neisseria gonorrhea among adolescents and young adults living with HIV in Eswatini
Neil Thivalapill, Harvard T.H. Chan School of Public Health, United States
Abstract
Slides
PEB0169 Performance of self-collected specimens for the detection of Chlamydia trachomatis and Neisseria gonorrhoeae infection
Gabriella Marie Vavala, University of California, Los Angeles., United States
Abstract
Slides
PEB0170 Frequency of detectable HIV viremia and immune suppression episodes as determinants of neurocognitive dysfunction in Ugandans with chronic HIV infection
Amara, Esther Ezeamama, Michigan State University, United States
Abstract
Slides
PEB0171 Neurocognitive function assessed via a self-administered tablet-based digital platform among people with HIV seeking adult clinical care
Keri Althoff, Johns Hopkins University, United States
Abstract
PEB0172 The Neurocognitive Assessment in the Metabolic and Aging Cohort (NAMACO) study: Evolution of neurocognitive diagnosis from baseline to two years follow-up
José Damas, Lausanne University Hospital, Switzerland
Abstract
Slides
PEB0173 Tryptophane metabolites predict neurocognitive impairment and side effects during efavirenz
Giuseppe Lapadula, "San Gerardo" Hospital, Italy
Abstract
Slides
PEB0174 Association between depressive symptoms and adherence among adolescents living with HIV in the Republic of Congo
Martin Herbas Ekat, Ambulatory Treatment Center of Brazzaville, Congo
Abstract
Slides
PEB0176 Patient age and cervical lesion severity by HIV-status: The first 13 months of VIA and cryotherapy/thermocoagulation implementation in Namibia
S.Laura Muzingwani, International Training and Education Center for Health (I-TECH), Namibia
Abstract
Slides
PEB0177 Cervical cancer screening: Experience from the Cameroon Baptist Convention Health Services women health program
Bonghaseh Dianna Mbu, Etoug-Ebe Baptist Hospital, Cameroon
Abstract
Slides
PEB0178 Associations of viremia and antiretroviral therapy duration with VIA positivity in Malawi: A retrospective analysis
Samuel Lewis, University of California, Los Angeles, United States
Abstract
Slides
PEB0179 Prevalence and predictors of hypertension stratified by HIV status in Kisumu, Kenya
Jerusha Mogaka, University of Washington, United States
Abstract
Slides
PEB0180 Cardiovascular and metabolic comorbidities in HIV-infected patients in Colombia: A multicenter study
Sandra Valderrama-Beltrán, Hospital Universitario San Ignacio, Colombia
Abstract
PEB0181 Patterns of antiretroviral use and immunologic correlates in the REPRIEVE trial at study entry
Carl Fichtenbaum, University of Cincinnati, United States
Abstract
PEB0182 Increased epicardial adipose tissue volume in virally suppressed older HIV-infected Asian and Relationships to central fat accumulation and lipodystrophy
Anchalee Avihingsanon, HIV-NAT, Thai Red Cross AIDS Research Centre, Thailand
Abstract
Slides
PEB0183 Increased IL1-β production during chronic HIV-infection; a role for innate reprogramming
Wouter A. van der Heijden, Radboud University Medical Center, Netherlands
Abstract
Slides
PEB0184 Association of antiretroviral therapy with myocardial deformation in antiretroviral therapy-naive HIV-infected patients
Han Siong Toh, Chimei Medical Center, Taiwan, Province of China
Abstract
Slides
PEB0185 Is hypertension more prevalent in HIV patients? A cross-sectional study from Rwanda
Bienvenu Niyongabo, AIDS Healthcare Foundation, Rwanda
Abstract
Slides
PEB0186 WHO HEARTS Treatment protocol facilitates integration of hypertension management into HIV care and improves blood pressure control at the largest HIV clinic in Uganda
Martin Muddu, Makerere University Joint AIDS Program (MJAP), Uganda
Abstract
Slides
PEB0187 Cardiovascular risk estimation is sub-optimal across two HIV cohorts
Virginia Triant, Massachusetts General Hospital, United States
Abstract
Slides
PEB0188 Bone accrual in children with perinatally acquired HIV compared to healthy children
Denise Jacobson, Harvard T.H. Chan School of Public Health, United States
Abstract
Slides
PEB0189 The importance of bone mass discordance in the diagnosis of osteoporosis in people living with HIV
Pilar Vizcarra, Hospital Universitario Ramón y Cajal, Spain
Abstract
Slides
PEB0190 CD4 nadir and CD4/CD8 ratio are associated with bone remodelling
Nicola Squillace, ASST-MONZA, San Gerardo Hospital, Italy
Abstract
Slides
PEB0191 Validation of D:A:D Chronic kidney disease risk score model among people living with HIV in Asia
Win Min Han, Kirby Institute, UNSW, Australia
Abstract
Slides
PEB0192 TDF renal safety in HBV-infected, HIV-negative women during pregnancy and post-partum period
Geoffroy Liegeon, Hôpital Saint-Louis, Assistance Publique - Hôpitaux de Paris, France
Abstract
Slides
PEB0193 A study of effect of Anti-Retroviral Therapy (ART) regimen on Metabolic Syndrome (MetS) in people living with HIV/AIDS (PLHIV) in India: A comprehensive post hoc analysis
Anchit Singh, Armed Forces Medical College, India
Abstract
Slides
PEB0194 Weight/body mass index (BMI) gains following initiation of integrase strand transfer inhibitor (INSTI) versus protease inhibitor (PI) among people living with human immunodeficiency virus (PLWH) in the United States
Wing Chow, Janssen Scientific Affairs, LLC, United States
Abstract
Slides
PEB0195 So much to lose: A review of 25 bariatric surgery cases in people living with HIV (PLWH) at an urban, Ryan White-funded HIV clinic
Marcelo Gareca, Lehigh Valley Health Network, United States
Abstract
Slides
PEB0196 Impact of weight gain on prescribing behavior for HIV patients on integrase inhibitor regimens using real world data
S.I. Gubernick, IQVIA, United States
Abstract
Slides
PEB0197 Weight gain associated with antiretroviral therapy in HIV-infected individuals is affected by multiple factors
Wei Cao, Peking Union Medical College Hospital, China
Abstract
PDF
PEB0198 Tenofovir alafenamide (TAF) does not increase weight in people living with HIV (PLWH)
Kayla Natali, Saint Michael's Medical Center, United States
Abstract
Slides
PEB0199 Weight change before and after switching therapy to tenofovir alafenamide (TAF) in virologically suppressed (VS) persons
Kayla Natali, Saint Michael's Medical Center, United States
Abstract
Slides
PEB0200 Changes in body mass index among people living with HIV who are new on highly active antiretroviral therapy: A systematic review and meta-analysis
John Olawepo, School of Public Health, University of Nevada Las Vegas, United States
Abstract
Slides
PEB0201 Risk of weight gain (WG) according to type of switching strategy in a large cohort of HIV-infected individuals with stable suppressed HIV-RNA
stefania cicalini, National Institute for Infectious Diseases, Italy
Abstract
Slides
PEB0202 Greater weight gains found in ART-experienced Nigerian patients switching to DTG than in EFV-based patients at 18-months follow-up
Jennifer Campbell, Clinton Health Access Initiative, United States
Abstract
PEB0203 Effect of dolutegravir on weight in persons living with HIV in Haiti
Patrice Severe, GHESKIO, Haiti
Abstract
PEB0204 Diabetes mellitus is associated with incident liver cirrhosis in people living with HIV in Thailand: A prospective cohort analysis
Thornthun Ueaphongsukkit, HIV-NAT, Thai Red Cross AIDS Research Centre, Thailand
Abstract
Slides
PEB0206 Associations between diet quality, the intestinal microbiome, and liver fibrosis in people living with HIV (PLWH) in the MASH cohort
Sabrina Martinez, Florida International Unviersity, United States
Abstract
Slides
PEB0207 Is NAFLD the same disease in HIV infected patients?
Sara Policarpo, Faculdade de Medicina Universidade de Lisboa, Portugal
Abstract
Slides
PEB0209 Suicidal thoughts and attempts among HIV-positive trans women in TransAmigas study, São Paulo, Brazil
Paula Galdino Cardin de Carvalho, Faculty of Medical Sciences of Santa Casa de São Paulo, Brazil
Abstract
Slides
PEB0210 Depression and associated factors among ART patients in Ukraine
Kostyantyn Dumchev, Ukrainian Institute on Public Health Policy, Ukraine
Abstract
PDF
PEB0211 Evaluation of the implementation of a comprehensive HIV and aging program in a large urban HIV clinic: The Golden Compass program
Meredith Greene, Zuckerberg San Francisco General Hospital, United States
Abstract
Slides
PEB0212 Long term impact of abacavir and tenofovir (TDF or TAF) on blood telomere length
Rocio Montejano, Hospital Universitario La Paz - IdiPAZ, Spain
Abstract
Slides
PEB0213 Aging with HIV: Using treatment cascades to identify gaps in the provision of care to people living with HIV (PLWH)
Reena Rajasuriar, University of Malaya, Malaysia
Abstract
Slides
PEB0214 Prevalence and severity of neurocognitive dysfunction in age, sex and demographically matched people with HIV and community dwelling HIV-uninfected Ugandan seniors
Amara, Esther Ezeamama, Michigan State University, United States
Abstract
Slides
PEB0215 Comparison of the frailty score and the Pooled Cohort Equations in predicting cardiovascular disease among persons with HIV
Frank Palella, Northwestern University Feinberg School of Medicine, United States
Abstract
Slides
PEB0216 Older adults with HIV are not all the same. Data from the HIV-funcfrail cohort
Matilde Sanchez-Conde, HOSPITAL RAMON Y CAJAL, Spain
Abstract
PEB0217 To dose-adjust or not to dose-adjust: 3TC dose in renal impairment
Karam Mounzer, University of Pennsylvania, United States
Abstract
Slides
PEB0218 Racial disparities in hospitalizations among persons living with HIV (PLWH) in the US and Canada, 2005-2015
Thibaut Davy-Mendez, University of North Carolina at Chapel Hill, United States
Abstract
Slides
PEB0219 Evaluation of health-related quality of life of people living with HIV in Taiwan
Ling Ya Chen, National Taiwan University Hospital, Taiwan, Province of China
Abstract
Slides
PEB0220 Factors associated with self-reporting of adverse events in Brazil: Results from a real-life cohort of PLHIV using DTG-containing regimens
Lino Neves da Silveira, Ministry of Health of Brazil, Brazil
Lino Neves da Silveira, Brazilian Ministry of Health, Brazil
Abstract
Slides
PEB0221 Medication burden and adverse drug reactions during the initial six months of antiretroviral treatment
Genesis Huerta, Instituto de Medicina Tropical "Alexander von Humboldt", Peru
Abstract
Slides
PEB0222 Dolutegravir-related adverse events: Results from the active pharmacovigilance implemented in Brazil
Fernanda Fernandes Fonseca, Ministry of Health, Brazil
Abstract
Slides
PEB0223 Measuring therapy tolerance through PROMS as part of routine clinical HIV care: Evaluating two years of experience
Godefridus van den Berk, OLVG, Netherlands
Abstract
PEB0224 Pilot trial of a novel behavioral activation/problem solving smoking cessation intervention for people living with HIV in Botswana
Billy Tsima, University of Botswana, Botswana
Abstract
Slides
PEB0225 Prevalence of low lean mass in people living with HIV on antiretroviral therapy
Pilar Vizcarra, Hospital Universitario Ramón y Cajal, Spain
Abstract
PDF
PEB0226 Levels of matrix metalloproteinases (MMPs) in HIV-infected children and adolescents with airway obstruction
Evgeniya Sovershaeva, UiT The Arctic University of Norway, Norway
Abstract
Slides
PEB0227 Delays in solid organ transplant evaluation among HIV-infected patients
Georges Ambaraghassi, Centre Hospitalier de l'Université de Montréal, Canada
Abstract
Slides
PEB0228 High abstinence rates from a smoking cessation program embedded within an HIV clinic
Mehri McKellar, Duke University, United States
Abstract
Slides
PEB0229 The BICSTaR prospective cohort: Real-world effectiveness, safety and tolerability of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in routine clinical practice in people living with HIV (PLWH)
Olivier Robineau, University of Lille, Hospital of Tourcoing, France
Abstract
Slides
PEB0230 Very high baseline HIV viremia impairs efficacy of NNRTI-based ART: A long-term observation in treatment-naïve patients
Shuai Chen, Peking Union Medical College Hospital, China
Abstract
Slides
PEB0231 CD4:CD8 ratio normalization with modern antiretroviral regimens
sharon walmsley, University Health Network, Canada
Abstract
Slides
PEB0232 Second-line dolutegravir or protease inhibitor for adults with HIV in rural Haiti with virologic failure on a first-line NNRTI-based regimen without available genotype
Georgery CONSTANT, Zanmi Lasante, Haiti
Abstract
Slides
PEB0233 Weight change among treatment naive women initiating dolutegravir in the ARIA study
sharon walmsley, University Health Network, Canada
Abstract
Slides
PEB0234 Clinical outcomes of heavily treatment experienced individuals in the OPERA Cohort
Ricky Hsu, AIDS Healthcare Foundation, United States
Abstract
Slides
PEB0235 Real life study with dual therapy in a HIV-1 treatment experienced Portuguese cohort
Rosa Correia, Universidade do Minho, Portugal
Abstract
Slides
PEB0236 Persons Living With HIV (PLWH) in Japan on 2-drug regimen reveal more complex patient profiles than that of a 3-drug regimen cohort
Daniel Ruzicka, MSD K.K., Japan
Abstract
Slides
PEB0237 Durability of dual antiretroviral regimens and factors associated with discontinuation in the clinical practice
Pilar Vizcarra, Hospital Universitario Ramón y Cajal, Spain
Abstract
PDF
PEB0238 Comparison of viral replication at <40c/mL for 2-drug regimen (2DR) of dolutegravir/lamivudine (DTG/3TC FDC) versus 3-drug regimen (3DR) based on tenofovir alafenamide (TAF) (TBR) in the TANGO study
Ruolan Wang, ViiV Healthcare, United States
Abstract
Slides
PEB0239 Patient's satisfaction in the context of a dual therapy and a simplified, patient-centred monitoring strategy for management of HIV infection: A Swiss non-inferiority, randomized, controlled, clinical trial (SIMPL'HIV)
Annalisa Marinosci, Hôpitaux Universitaires de Genève, Switzerland
Abstract
Slides
PEB0240 Factors associated with virological failure (VF) in HIV-1 subjects receiving dolutegravir monotherapy (DTG-m) as maintenance therapy: A meta-analysis of individual patients data (IPDMA)
Anna L. Fournier, CHU de Caen, France
Abstract
Slides
PEB0241 Virological efficacy and tolerability of dual therapy maintenance with dolutegravir plus lamivudine in heavily treatment experienced HIV-infected patients: Four years data from DOLULAM study
Jacques Reynes, Montpellier University Hospital, France
Abstract
Slides
PEB0242 Sufficient plasma levels within 24 weeks of antiretroviral HIV therapy of dolutegravir combined with boosted darunavir: A pharmacologic subgroup analysis of the DUALIS study
Simon Weidlich, Technical University Munich, School of Medicine, University Hospital recht der Isar, Department of Medicine II, Germany
Abstract
PDF
PEB0243 Pharmacogenomics and pharmacokinetics of Efavirenz 400mg in treatment-naive HIV-infected patients: A 48-weeks outcome of a lower dose ART regime study in China
Rong Chen, Shanghai Public Health Clinical Center, Fudan University, China
Abstract
Slides
PEB0244 Pharmacokinetic and pharmacogenetic associations between efavirenz-based regimens and neurocognitive performance in People Living With HIV in Nigeria
Jacinta Nwogu, University of Ibadan, Nigeria
Abstract
Slides
PEB0245 Hair concentration of antiretroviral drugs, but not self-reported adherence, is associated with ongoing virologic failure among individuals in Resource Limited Settings (RLS) on second line Antiretroviral Therapy (ART)
Tanakorn Apornpong, HIV-NAT, Thai Red Cross AIDS Research Centre, Thailand
Abstract
Slides
PEB0246 Role of cytochrome CYP2B6 polymorphisms on nevirapine plasma levels and clinical outcomes. A prospective study among HIV-1 infected patients receiving ART treatment in Nairobi Kenya
Musa Ngayo, Kenya Medical Research Institute, Kenya
Abstract
PEB0247 Maternal and neonatal effects of antiretroviral therapy with efavirenz in pregnant women with human immunodeficiency virus
Helena Barbi, Unicamp College of Medical Sciences, Brazil
Abstract
Slides
PEB0248 Polyherbacy among people living with HIV in resource limited settings: Implication for drug-herb interactions
Zewdneh Sabe, CDT-Africa, Addis Ababa University, Ethiopia
Abstract
Slides
PEB0250 Inflammation, immune activation and microbial translocation in persons living with four-class drug resistant HIV: Data from the PRESTIGIO registry
Vincenzo Spagnuolo, Vita-Salute San Raffaele University, Italy
Abstract
Slides
PEB0251 Viral C-Terminal region P7 – P6gag Gag polymorphisms and protease drug resistance mutations profile in HIV-1 infected patients failing protease Inhibitors combination therapy
Georges teto, CIRCB, Cameroon
Abstract
Slides
PEB0252 Use of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) beyond the presence of the M184V mutation
Kayla Natali, Saint Michael's Medical Center, United States
Abstract
Slides
PEB0253 High efficacy after switching to Integrase Strand Transfer Inhibitors (INSTI) in PLWH with undetectable viremia and past virological failure with or without resistance
Abstract
PEB0254 Prevalence and risk factors of pre-existing NNRTI resistance among suppressed PLWH in B/F/TAF switch studies
Kristen Andreatta, Gilead Sciences, United States
Abstract
Slides
Slides
PEB0255 NRTI mutations scenario in Europe: How they have changed and their implication in HIV prevention and therapy
Davide Moschese, Catholic University of Sacred Heart, Italy
Abstract
Slides
PEB0256 Durability of second-line anti-retroviral therapy and predictors of viral rebound among HIV patients on second-line ART in an HIV specialist clinic in Uganda: A 10-year retrospective cohort
Ivan Lumu, Infectious Diseases Institute, Makerere University College of Health Sciences, Uganda
Abstract
Slides
PEB0257 Baseline NRTI resistance in suppressed participants did not lead to viral blips on bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) or dolutegravir (DTG)+F/TAF through week 48 in study 380-4030
Rima Acosta, Gilead Sciences, United States
Abstract
Slides
PEB0258 HIV drug resistance (HIVDR) in Haiti: Impact on future guidelines
Serena Koenig, Brigham and Women's Hospital, United States
Samuel Pierre, GHESKIO Centers, Haiti
Abstract
PEB0259 Non-nucleoside inhibitors-acquired HIV resistance in Mexico: Is there Doravirine cross-resistance?
Juan Pablo Ramirez Hinojosa, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico
Abstract
Slides
PEB0260 Feasibility of implementing long-acting injectable anti-retroviral therapy to treat HIV: A survey of health providers from the 13 countries participating in the ATLAS-2M trial
Deanna Kerrigan, George Washington University, United States
Abstract
Slides
PEB0261 Patient-reported outcomes through week 48 of ATLAS-2M: A study of long‑acting cabotegravir and rilpivirine administered every four or eight weeks
Vasiliki Chounta, ViiV Healthcare (UK), United Kingdom
Abstract
Slides
PEB0262 Willingness to use injectable antiretroviral therapy (ART) among women who disengage from prevention of mother-to-child transmission programmes in Uganda
Eva Laker Odongpiny, The Infectious Diseases Institute, Uganda
Abstract
Slides
PEB0263 Compassionate use of long acting (LA) cabotegravir (CAB) and rilpivirine (RPV) for patients in need of parenteral antiretroviral therapy
Ronald D’amico, ViiV Healthcare, United States
Abstract
Slides
PEB0264 Population pharmacokinetic (PopPK) modeling and simulation of monthly intramuscular (IM) long-acting rilpivirine (RPV LA) to inform strategies following dosing interruptions in HIV-1 infected subjects
Bryan Baugh, Janssen Pharmaceutica, United States
Abstract
PEB0265 GS-6207 sustained delivery formulation supports 6-month dosing interval
Rebecca Begley, Gilead Sciences Inc, United States
Abstract
Slides
PEB0266 Antiretroviral therapy adherence in India (2012-18): A systematic review and meta-analysis
Saurav Basu, MAULANA AZAD MEDICAL COLLEGE, India
Abstract
Slides
PEB0267 High rates of nurse-led rapid ART start and subsequent linkage to care/viral suppression at a large community-based HIV testing and prevention site in San Francisco, California, USA
Katerina Christopoulos, University of California San Francisco, United States
Abstract
PEB0268 High treatment retention rates among patients with multi-month antiretroviral therapy (ART) supply from HIV clinic settings in Nigeria
Juliet Adeola, APIN Public Health Initiatives, Nigeria
Abstract
Slides
PEB0269 Rates, patterns and predictors of non-adherence to ART regimens in Kenya
Zachary Kwena, Kenya Medical Research Institute, Kenya
Abstract
Slides
PEB0270 Outcomes of suspected treatment failure in a cohort of ART patients in Kenyatta National Hospital, Kenya
Kenneth Mutai, Kenyatta National Hospital, Kenya
Abstract
Slides
PEB0271 Perception and willingness to participate in HIV cure clinical trials among people who initiated treatment during acute HIV infection in Amsterdam
Maartje Dijkstra, Public Health Service Amsterdam, Netherlands
Abstract
PDF
PEB0272 A landscape analysis of HIV cure-related clinical research in 2019
Liz Barr, University of Maryland, United States
Abstract
Slides
Slides
Slides
PEB0273 Influence of a Supplemented Mediterranean Diet on the gut microbiome profile in HIV-1 infected individuals
Roque Pastor-Ibáñez, Hospital Clinic de Barcelona, Spain
Abstract
Slides
PEB0274 Main results of the active pharmacovigilance strategy in women living with HIV on DTG-containing regimens in Brazil
Lino Neves da Silveira, Brazilian Ministry of Health, Brazil
Abstract
Slides
PEB0275 Women on ART are less likely to achieve HIV RNA <50 cop/ml compared to men – Real world data from the National Swedish InfCare Cohort
Åsa Mellgren, University of Gothenburg, Sweden
Abstract
Slides
PEB0276 Reverse transcriptase and protease inhibitors mutational viral load in HIV infected pregnant women with transmitted drug resistance in Argentina
Diego Cecchini, Hospital Cosme Argerich, Argentina
Abstract
Slides
PEB0277 Extent of in utero transfer of tenofovir from mother to fetus: A paired analysis of hair specimens collected at birth from a cohort in the United States
Jillian Pintye, University of Washington, United States
Abstract
Slides
PEB0278 Viral suppression by delivery and birth outcomes among pregnant women living with HIV using dolutegravir in the United States: A comparative effectiveness and safety analysis
Kunjal Patel, Harvard T.H. Chan School of Public Health, United States
Abstract
Slides
PEB0280 Integration of HIV and obstetric care to optimize HIV management during and after pregnancy
Charitha Gowda, Nationwide Childrens' Hospital, United States
Abstract
Slides
PEB0281 Longitudinal evolution of maternal viral load during pregnancy and within 12 months postpartum among pregnant women living with HIV in South Africa
Faith Moyo, National Institute for Communicable Diseases, National Health Laboratory Service, South Africa
Abstract
Slides
PEB0282 The challenge of perinatally HIV-infected women during pregnancy
Talia Sainz, Hospital La Paz and IdiPAZ, Spain
Abstract
PDF
PEB0283 Contraception uptake among HIV positive women on dolutegravir based antiretroviral treatment in urban Uganda: A cross sectional survey
Leah Mbabazi, Infectious Diseases Institute (IDI), Uganda
Abstract
Slides
PEB0284 Changuo Langu: Is it really her choice? Examining healthcare provider perspectives on dolutegravir and contraceptive counselling for women of reproductive age at a tertiary referral centre in Western Kenya
Julie Thorne, University of Toronto / Women's College Hospital, Canada
Abstract
Slides
PEB0285 Chaguo Langu - My Choice: Use of a new pregnancy preference scale among women of reproductive potential living with HIV using dolutegravir
Caitlin Bernard, Indiana University School of Medicine, United States
Abstract
Slides
PEB0286 Chaguo Langu - My Choice: Patient perspectives on counseling and shared decision-making around antiretroviral therapy and contraceptive choices
Caitlin Bernard, Indiana University School of Medicine, United States
Abstract
Slides
PEB0287 Clinical outcome among HIV diagnosed children under Early Infant Diagnosis (EID) programme in India: Addressing the gaps for further improvement
SUCHIT KAMBLE, ICMR-National AIDS Research Institute, India
Abstract
Slides
PEB0288 Shared risk profiles for vertically HIV-infected infants and HIV-exposed infants without early infant diagnostic (EID) test results - unrecognized HIV transmission to infants in Ethiopian prevention-of-mother-to-child transmission (PMTCT) programs?
John Walles, Lund University, Sweden
Abstract
Slides
PEB0289 Assessment, feasibility, and acceptability of an adapted HIV risk screening tool to identify undiagnosed children living with HIV in Burundi
Adonis Ndayizeye, FHI 360 Reaching an AIDS-Free Generation (RAFG), Burundi
Abstract
Slides
PEB0290 Negative diagnostic PCR results among very early treated infants in Johannesburg, South Africa
Megan Burke, University of Witwatersrand, South Africa
Abstract
Slides
PEB0291 Model-based approach of dose selection and optimal PK sampling of fostemsavir for pediatric patients with multidrug resistant HIV-1 infection
Nilay Thakkar, GlaxSmithKline, United States
Abstract
Slides
PEB0292 Implementation of lopinavir-boosted ritonavir as preferred first-line in children living with HIV in six regions-Tanzania
Theopista Jacob Masenge, Elizabeth Glaser Pediatric Aids Foundation, Tanzania, United Republic of
Abstract
Slides
PEB0293 Twenty-four week safety, tolerability and efficacy of dolutegravir dispersible tablets in children 4 weeks to <6 years old with HIV: Results from IMPAACT P1093
Theodore Ruel, UCSF Benioff Children's Hospital, United States
Abstract
PDF
PEB0294 Safety of Early Infant Male Circumcision (EIMC) in a trial of the ShangRing versus the Mogen Clamp in Rakai, Uganda
Stephen Kiboneka, Rakai Health Sciences Program, Uganda
Abstract
Slides
PEB0295 Where are we on the optimization of pediatric ART services? Review of care packages in children under 10, Tanzania
Theopista Jacob Masenge, Elizabeth Glaser Pediatric Aids Foundation, Tanzania, United Republic of
Abstract
Slides
PEB0296 Virological characterization in newly HIV diagnosed adolescents in Spain during 1980-2017
Carolina Beltrán-Pavez, Hospital Ramón y Cajal- IRYCIS, Spain
Cristina Epalza, Hospital 12 de Octubre, Spain
Abstract
Slides
PEB0297 The "D.T.G.s" of DTG for children and adolescents living with HIV (CALHIV): Descriptions, trends, and gaps of rolling out dolutegravir in CALHIV in Mbeya, Tanzania
Jason Bacha, Baylor College of Medicine Children´s Foundation-Tanzania, Tanzania, United Republic of
Abstract
Slides
PEB0298 Early trends in HIV drug resistance among children and young people (0-24 years) in Eswatini
Sarah Perry, Baylor College of Medicine, United States
Abstract
Slides
PEB0299 Prevalence of M184V and K65R in proviral DNA from PBMCs in HIV-infected adolescents with 3TC/FTC exposure
Carolina Beltrán-Pavez, Hospital Ramón y Cajal- IRYCIS, Spain
Santiago de Ory, Hospital General Universitario Gregorio Maranon, Spain
Abstract
PEB0300 Optimisation of first-line antiretroviral therapy (ART) for children living with HIV in Uganda: Translation from policy to action
Eleanor Namusoke Magongo, Ministry of Health, Uganda
Abstract
Slides
PEB0301 Low viral suppression among children receiving antiretroviral therapy in Nigeria
Olufemi Adegoke, US Centers for Disease Control and Prevention, Nigeria, Nigeria
Abstract
Slides
PEB0302 Tanzania's second act: To suppress or not to suppress? Viral load suppression and adherence after switching to second-line ART at Baylor Children's Center of Excellence in Mwanza, Tanzania
Vicki Ip, Baylor College of Medicine International Pediatric AIDS Initiative, Tanzania, United Republic of
Abstract
Slides
PEB0303 Achieving viral suppression among non-suppressed adolescents on ART in Tanzania: Effects of a targeted intervention
Theopista Jacob Masenge, Elizabeth Glaser Pediatric Aids Foundation, Tanzania, United Republic of
Abstract
Slides
PEB0304 High HIV viremia among adolescents aged 10-19 years on antiretroviral therapy receiving a scaled up differentiated service delivery in Malawi: Teen club experience
Rachel Chamanga, Elizabeth Glaser Pediatric AIDS Foundation, Malawi
Abstract
Slides
PEB0305 Retention of children compared to retention of women living with HIV in sub-Saharan Africa
Henry Miller, Office of the Global AIDS Coordinator, United States
Abstract
Slides
PEB0306 Leaving no teen behind: Results from Tanzania's first clinical HIV cascade analysis for adolescents
John George Ng'ariba, UNICEF, Tanzania, United Republic of
Abstract
Slides
PEB0307 Adolescents disengaged from HIV care in Kenya: Qualitative insights
Leslie Enane, Indiana University School of Medicine, United States
Abstract
PEB0308 Non-adherence and low drug levels impact viral outcomes in HIV-infected Kenyan youth
Rachel Vreeman, Icahn School of Medicine at Mount Sinai, United States
Abstract
Slides
PEB0309 Sex-specific factors associated with suboptimal adherence to antiretrovirals and detectable viral load among youth living with perinatal HIV in the United States (US)
Deborah Kacanek, Harvard TH Chan School of Public Health, United States
Abstract
Slides
PEB0310 Improving viral load suppression rates among HIV positive children on ART in a large volume HIV clinic in Western Uganda
Winnie Akobye, Baylor College of Medicine Children's foundation-Uganda., Uganda
Abstract
Slides
PEB0311 Isoniazid prophylaxis therapy completion rate and side effects among children on care and treatment in Mwanza, Tanzania
Judith Gwimile, Baylor College of Medicine Children's Foundation Tanzania, Tanzania, United Republic of
Abstract
Slides
PEB0312 Longitudinal changes in epigenetic age in youth with perinatally-acquired HIV (YPHIV) and youth who are perinatally HIV-exposed uninfected (YPHEU)
Stephanie Shiau, Rutgers School of Public Health, United States
Abstract
Slides
PEB0313 Youth living with perinatally-acquired HIV have lower physical activity levels as they age compared to HIV-exposed uninfected youth
Sahera Dirajlal-Fargo, Case Western Reserve University, United States
Abstract
PDF
PEB0314 Third-line compromise: Characterization of drug resistance in Ugandan children and adolescents failing second-line antiretroviral therapy
Amanda Small, Baylor Children's Foundation Eswatini, Eswatini
Abstract
Slides
PEB0315 A machine learning approach for predicting probability of death or disease progression in an early-treated pediatric African cohort
Sara Dominguez Rodriguez, Fundacion para la Investigacion Biomedica del Hospital 12 de Octubre, Spain
Abstract
Slides
PEB0316 Paclitaxel-ing a punch: Successful treatment of children, adolescents, and young adults with relapsed or refractory Kaposi sarcoma with paclitaxel in Mbeya, Tanzania
Nadiya Alnoor Jiwa, Baylor College of Medicine Children's Foundation Tanzania, Tanzania, United Republic of
Abstract
Slides
PEB0317 Antibody responses to tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccination among perinatally HIV-infected Thai adolescents stable on combination antiretroviral treatment
Tavitiya Sudjaritruk, Faculty of Medicine, Chiang Mai University, Thailand
Abstract
Slides
PEB0318 Safety and immunogenicity of live-attenuated Japanese encephalitis vaccination among perinatally HIV-infected Thai adolescents stable on combination antiretroviral treatment
Tavitiya Sudjaritruk, Faculty of Medicine, Chiang Mai University, Thailand
Abstract
Slides
PEB0319 Factors associated with necrotizing enterocolitis in a public hospital in Johannesburg, South Africa, 2013 – 2018: A cross sectional study
Oluseyi Ajayi, University of the Witwatersrand, South Africa
Abstract
Slides
PEB0320 The role of behavioral and neurocognitive functioning in substance use among youth with perinatally acquired HIV infection and perinatal HIV exposure without infection
Sharon Nichols, University of California, San Diego, School of Medicine, United States
Abstract
Slides
PEB0321 Retention in care among adolescents living with HIV in Cape Town, South Africa
Millicent Atujuna, University of Cape Town, Desmond Tutu HIV Centre, South Africa
Abstract
Slides
PEB0322 Neurocognitive function in HIV-infected children on protease inhibitor based versus non- protease inhibitor based antiretroviral therapy
Damalie Nalwanga, Makereere University, College of Health Sciences, Uganda
Abstract
Slides
PEB0324 Prevalence and factors associated with depression and suicidality among adolescents living with HIV attending the HIV adolescence clinic at KCMC Hospital in Tanzania
Aisa Shayo, Kilimanjaro Christian Medical Center, Tanzania, United Republic of
Abstract
Slides
PEB0325 Lessons learned from impact of mental health care integration into HIV adolescent same day antiretroviral services on drug adherence and care retention in Bangkok, Thailand
Chutima Saisaengjan, Chulalongkorn University, Thailand
Abstract
Slides
PEB0326 Mental health and quality of life in children living with HIV on antiretroviral therapy
Stephanie Shiau, Rutgers School of Public Health, United States
Abstract
Slides
PEB0327 Neurodevelopment at 12 months of age among very early treated infants in Johannesburg, South Africa
Renate Strehlau, University of the Witwatersrand, South Africa
Abstract
Slides
PEB0328 Associations of Nevirapine-based ART regimens with neuropsychological outcomes in HIV-positive children
Lee Fairlie, Wits Reproductive Health & HIV Institute (Wits RHI), Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, South Africa
Abstract
Slides
PEB0329 Beyond survival – strategies to promote the quality of life of HIV infected young adults at Botswana-Baylor
Grace Karugaba, Botswana-Baylor Children's Clinical Centre of Excellence, Botswana
Abstract
Slides
PEB0330 Infant morbidities differentials of HIV positive mothers with known vaginal dysbiosis status: A statistical analysis with a skewed binary outcome using generalised estimating equations
ngugi mwenda, moi university, Kenya
Abstract
Slides
PEB0331 Mapping cortical structure and neurocognitive development of HIV-exposed uninfected children in South Africa: Neuroimaging outcomes from a South African birth cohort
Catherine J. Wedderburn, London School of Hygiene & Tropical Medicine, United Kingdom
Abstract
PEB0332 Improvement in timely infant HIV testing following monitoring of estimated date of delivery (EDD) and quality reporting for the urban districts of Kampala and Wakiso, Uganda
Zikulah Namukwaya, Infectious Diseases Institute (IDI), Makerere University, Uganda
Abstract
Slides
PEB0333 Hospitalization is associated with seroconversion to parainfluenza and respiratory syncytial virus in HIV-exposed, uninfected infants born in the United States
Christiana Smith-Anderson, University of Colorado, United States
Abstract
Slides
PEB0334 Double trouble: Increased risk of congenital cytomegalovirus infection among HIV-exposed newborns
Fatima Kakkar, CHU Sainte-Justine, University of Montreal, Canada
Abstract
PEB0335 Risk factors for small for gestational age and microcephaly among HIV exposed uninfected infants in Montreal, Canada
Fatima Kakkar, CHU Sainte-Justine, University of Montreal, Canada
Abstract
PEB0336 Social support and viral suppression in young adults with perinatally-acquired HIV in the United States
Katherine Tassiopoulos, Harvard T. H. Chan School of Public Health, United States
Abstract
Slides
PEB0337 Virological outcome among vertically HIV infected patients transferred from pediatric care to adult units in Madrid
Carolina Beltrán-Pavez, Hospital Ramón y Cajal- IRYCIS, Spain
Ana Valadés, Hospital Ramón y Cajal - IRYCIS, Spain
Abstract
Slides
PEB0338 The patient-provider relationship and transition from adolescent to adult focused HIV care: An international qualitative metasynthesis
Emily Barr, University of Colorado Children's Hospital Colorado, United States
Abstract
Slides
PEB0339 Sustainability of the HIV care cascade among adolescents and young adults transitioning to adult HIV care
Marilia Bordignon Antonio, Universidade de São Paulo/ Hospital das Clínicas HCFMUSP, Brazil
Abstract
Slides
PEB0340 Worse virological response and deficient immunological recovery in young adults with vertical transmission of HIV after transition to adult care
Anna Celotti, University of Brescia and ASST Spedali Civili Hospital of Brescia, Italy
Abstract
Slides
PEB0341 Ending the HIV epidemic: Rapid ART start at The Detroit STD Clinic
Shira Heisler, Wayne State University/Detroit Public Health STD Clinic, United States
Abstract
Slides
PEB0342 Offer of a triple rapid HIV/HBV/HCV testing to three exposed populations, including MSM, in distinct community-healthcare centres in Paris Area (ANRS-SHS-154-CUBE study)
Nicolas Derche, ARCAT / GROUPE SOS, France
Abstract
Slides
PEB0343 Youth vulnerable to delayed ART initiation in a cohort of MSM in Hanoi, Vietnam
Ramona Bhatia, CDC, Vietnam
Abstract
Slides
PEB0344 Syphilis prevalence and incidence among HIV negative men who have sex with men and transgender women in Buenos Aires, Argentina
Luciana Spadaccini, Fundacion Huesped, Argentina
Abstract
Slides
PEB0346 Prevalence and independent risk factors of HIV and syphilis infections among Thai transgender women who have undergone vaginoplasty procedures
Worapon Ratanalert, PREVENTION, Thai Red Cross AIDS Research Centre, Thailand
Abstract
Slides
PEB0347 Illicit opioid use following changes in opioids prescribed for chronic non-cancer pain among persons living with and without HIV
Phillip Coffin, San Francisco Department of Public Health, United States
Abstract
Slides
PEB0348 Pursuing 90-90-90 targets in Russia: Addiction Hospital as a reachable moment for HIV care engagement
Jeffrey Samet, Department of Medicine, Section of General Internal Medicine, Boston University School of Medicine/Boston Medical Center, United States
Abstract
Slides
PEB0349 Opioid use is associated cognitive impairment in people living with HIV from the MASH cohort
Javier Tamargo, Florida International University, United States
Abstract
Slides
PEB0350 Cocaine, inflammation and the gut microbiome in the MASH cohort
Sabrina Martinez, Florida International Unviersity, United States
Abstract
PEB0351 Associations between methamphetamine use and lack of viral suppression among a cohort of HIV positive persons who inject drugs in Hai Phong, Vietnam
Jonathan Feelemyer, New York University, United States
Abstract
Slides
PEB0352 Drug use, inflammation and cardiac mechanical overload in women living with HIV who experience homelessness and housing instability
Elise Riley, University of California, San Francisco, United States
Abstract
Slides
PEB0353 High prevalence of HIV, viral hepatitis B, C and syphilis among male prisoners in Thailand
Ruamthip Supanun, Medical Correctional Hospital, Thailand
Abstract
Slides
PEB0354 Characteristics of people with HIV (PWH) and HIV treatment outcomes in community practices in southern vs non-southern US regions
Keith Rawlings, ViiV Healthcare, United States
Abstract
Slides
Slides
Slides
PEB0355 The influence of gender, age, place of birth and way of acquisition on disparities in the HIV care continuum in France
Lise Cuzin, Martinique University Hospital, Martinique
Abstract
PDF
PEB0356 Neural tube defects and adverse pregnancy outcomes after maternal exposure to dolutegravir and other antiretroviral medications during pregnancy, United States, 2013-2017
Karen Hoover, Centers for Disease Control and Prevention, United States
Abstract
PEB0358 Isoniazid tuberculosis preventive therapy toxicity among HIV-positive children, adolescents and adults in Uganda
Jacqueline Kanywa, Baylor College of Medicine Children's Foundation Uganda, Uganda
Abstract
Slides
PEB0359 Efficacy, safety, and tolerability of switching efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in virologically suppressed adults with HIV-1 infection
Erik Lowman, Midland Research Group, United States
Abstract
Slides